Melinta Therap 
Welcome,         Profile    Billing    Logout  
 6 Products   1 Disease  6 Products   14 Trials   2291 News 
23 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Nuvocid (oritavancin) / Melinta Therap, Menarini
COPAT, NCT05977868: Comparing Oral Versus Parenteral Antimicrobial Therapy

Terminated
4
90
US
Amoxicillin, amoxicillin-clavulanate, cefadroxil, cefpodoxime, cefalexin, ciprofloxacin, delafloxacin, doxycycline, levofloxacin, linezolid, metronidazole, moxifloxacin, rifampin, trimethoprim-sulfamethoxazole, Ampicillin, ampicillin-sulbactam, cefazolin, cefepime, ceftaroline, ceftazidime, ceftazidime-avibactam, dalbavancin, daptomycin, ertapenem, meropenem, oritavancin, oxacillin, penicillin, piperacillin-tazobactam, tigecycline, vancomycin
West Virginia University
Endovascular Infection, Bone and Joint Infection, Skin and Soft Tissue Infection, Pulmonary Infection, Gastrointestinal Infection, Genitourinary Infection
02/25
02/25
AIM-STOP, NCT05521880: Anchoring Sequential Intermittent Long Acting Antimicrobials With Medication for Opioid Use Disorder (MOUD) for Invasive Infections Related to Opioid Use

Terminated
4
2
US
Oritavancin
University of Maryland, Baltimore
Substance Use Disorders, Infection, Soft Tissue, Bacteremia, Osteomyelitis Acute, Septic Arthritis
05/25
05/25
2022-001297-63: A Multicenter, Open-Label, Evaluator-Blinded, Randomized Study to Evaluate the Safety and Tolerability of Single-Dose IV Oritavancin Versus Standard of Care for the Treatment of Pediatric Subjects with Acute Bacterial Skin And Skin Structure Infections

Ongoing
2
200
Europe
ORBACTIV®, KIMYRSA, Clindamycin, Teicoplanin, Vancomycin, Cafazolin, Ceftaroline, Sulfamethoxazole/trimetoprime, Lyophilisate for solution for infusion, Solution for infusion, Powder and solvent for solution for injection/infusion, Powder for concentrate for solution for infusion, Powder for solution for injection/infusion, Oral suspension, ORBACTIV®, KIMYRSA
Melinta Therapeutics, LLC, Melinta Therapeutics, LLC
Acute Bacterial Skin and Skin Structure Infections, Bacterial infection of the skin and associated tissues., Diseases [C] - Skin and Connective Tissue Diseases [C17]
 
 
ML-ORI-201, NCT05599295 / 2022-001297-63: Study to Evaluate the Safety and Tolerability of Single-Dose Intravenous (IV) Oritavancin

Recruiting
2
200
Europe, US
Oritavancin
Melinta Therapeutics, LLC, Melinta Therapeutics, LLC
Acute Bacterial Skin and Skin Structure Infection
06/25
01/26
NCT02134301 / 2013-005415-26: Open-Label, Dose-Finding, Pharmacokinetics, Safety and Tolerability Study of Oritavancin in Pediatric Patients With Suspected or Confirmed Bacterial Infections

Recruiting
1
52
US
Oritavancin
Melinta Therapeutics, LLC
Gram Positive Bacterial Infections
06/25
06/25
ORI-4-CIEDi, NCT07013552: Oritavancin for CIED Infections With MDR Gram-positive Cocci

Not yet recruiting
N/A
100
Europe
Administration of a single or repeated dose of a long half-life antibiotic - oritavancin, Administration of a repeated dose of a short half-life antibiotic - vancomycin
Medical University of Silesia, Medical Research Agency, Poland
Cardiac Implantable Electronic Device Infections, Infective Endocarditis, Multidrug-resistant Bacteria Screening, Gram Positive Bacterial Infection, Antibiotic Resistant Strain, Antibiotic Therapy, Healthcare Associated Infections
07/26
10/26
Rezzayo (rezafungin for injection) / Cidara Therap, Mundipharma, Melinta Therap
NCT06985758: Pharmacokinetic Study of Rezafungin in Patients With Suspected Intra-Abdominal Candidiasis

Not yet recruiting
4
20
Europe
Rezafungin 400mg followed by weekly doses of intravenous Rezafungin 200mg, Rezafungin
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
Candidal Peritonitis
11/25
01/26
ReSPECT, NCT04368559 / 2017-004981-85: Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation

Recruiting
3
600
Europe, Canada, US, RoW
Rezafungin for Injection, Intravenous antifungal therapy, Posaconazole, Noxafil, Fluconazole, Generic Fluconazole, Trimethoprim-sulfamethoxazole (TMP/SMX), Bactrim, Septra, Intravenous Placebo, Placebo Infusion, Oral Placebo, encapsulated cellulose
Mundipharma Research Limited
Candidemia, Mycoses, Fungal Infection, Fungemia, Invasive Candidiasis, Pneumocystis, Mold Infection, Invasive Fungal Disease, Prophylaxis of Invasive Fungal Infections, Aspergillus
12/25
12/25
NCT06774144: Rezafungin Prophylaxis in Liver Transplant

Enrolling by invitation
3
385
US
Rezafungin, Standard of care antifungal prophylaxis, Fluconazole, voriconazole, or no prophylaxis
Fernanda P Silveira, MD, MS, Melinta Therapeutics
Liver Transplant Infection, Fungal Infection
12/28
12/28
NCT05835479: Rezafungin for Treatment of Pneumocystis Pneumonia in HIV Adults

Recruiting
2
50
RoW
Co-Trimoxazole, Rezafungin Acetate / Co Trimoxazole
Mundipharma Research Limited
Pneumocystis Pneumonia
05/25
08/25
NCT06794554: Rezafungin for Treatment of Chronic Pulmonary Aspergillosis (CPA) in Adults with Limited Treatment Options

Not yet recruiting
2
60
NA
Rezafungin Acetate
Mundipharma Research Limited
Chronic Pulmonary Aspergillosis
02/26
07/26
NCT06329518: Rezafungin Pharmacokinetics in Patients on ECMO

Withdrawn
1
8
NA
Rezafungin, rezafungin acetate
Hartford Hospital, Melinta Therapeutics, LLC
Sepsis
12/24
12/24
NCT05534529: Rezafungin Paediatric PK Study in Paediatric Subjects From Birth to <18 Years of Age

Terminated
1
32
Europe
Rezafungin Acetate, Rezafungin
Mundipharma Research Limited
Invasive Fungal Infections
05/24
10/24
Vabomere (meropenem/vaborbactam) / Melinta Therap, Menarini
2021-003847-10: A study comparing a 7-day versus a 14-day course of antibiotics against an infection affecting the blood caused by a bacteria called Pseudomonas aeruginosa. Estudio en el que se compara un tratamiento con antibióticos de 7 días frente a uno de 14 días de duración contra una infección que afecta a la sangre producida por una bacteria llamada Pseudomonas aeruginosa.

Ongoing
4
304
Europe
Tablet, Solution for infusion, Powder for infusion, Powder for solution for infusion, Ciprofloxacin, Levofloxacin, Piperacillin/Tazobactam, Ceftazidime, Cefepime, Ceftazidime/Avibactam, Ceftolozane/Tazobactam, Imipenem, Meropenem, Meropenem-Vaborbactam, Colistin, Amikacin, Tobramycin, Aztreonam
Fundación Pública Andaluza para la Gestión de la Investigación en Salud de Sevilla (FISEVI), ICI21/00075 (ISCIII)
Adult patients with bloodstream infections produced by Pseudomonas aeruginosa. Pacientes adultos con bacteriemia producida por Pseudomonas aeruginosa., Adult patients with infections that produce the passing of Pseudomonas aeruginosa bacteria to the blood. Pacientes adultos con infecciones que producen el paso de bacterias de Pseudomonas aeruginosa a la sangre., Diseases [C] - Bacterial Infections and Mycoses [C01]
 
 
TREAT-GNB, NCT07004049: Optimising TREATment for Severe Gram-Negative Bacterial Infections

Recruiting
4
600
Europe, RoW
Colistin/Polymyxin B + Sulbactam, Colistin/Polymyxin B + Tigecycline/Eravacycline, Colistin/Polymyxin B + Meropenem, Ceftazidime-avibactam + Sulbactam, Ceftazidime-avibactam + Fosfomycin, Ceftazidime-avibactam, Ceftazidime-avibactam + Aztreonam, Ceftazidime-avibactam + Colistin/Polymyxin B, High-dose meropenem, Meropenem + Fosfomycin, Meropenem-vaborbactam, Cefiderocol, Ceftolozane-tazobactam, Ceftolozane-tazobactam + Meropenem
National University of Singapore, The University of Queensland, European Clinical Research Alliance for Infectious Diseases (ECRAID)
Bloodstream Infection, Ventilator Associated Bacterial Pneumonia, Hospital Acquired Bacterial Pneumonia, Carbapenem Resistant Bacterial Infection, Multidrug Resistance
12/28
12/28
2014-000545-78: A randomized, double-blind double-dummy Phase 3 study performed at multiple study sites to evaluate the safety, efficacy and tolerability of the combinational product Carbavance (Meropenem/RPX7009) in comparison to Piperacillin/Tazobactam which is already approved in many countries to treat patients with complicated urinary tract infections, including acute pyelonephritis, in adults.

Ongoing
3
80
Europe
Carbavance, Meropenem/RPX7009, Tazobac EF, Piperacillin/Tazobactam-Teva 4g/0,5g, Tazobac EF, Piperacillin/Tazobactam-Teva 4g/0,5g
Rempex Pharmaceuticals, Inc., Rempex Pharmaceuticals Inc., Biomedical Advanced Research and Development Authority (BARDA)
complicated urinary tract infection (cUTI) or acute pyelonephritis (AP) with or without concurrent bacteremia
 
 
VABOR-KIDS-01, NCT06828848: A Study to Assess How Vaborem® is Taking up in the Body and Tolerated in Paediatric Patients With Complicated Urinary Tract Infection

Recruiting
2
32
Europe, RoW
Meropenem plus vaborbactam
Menarini Group
Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis
07/26
07/26
NCT06672978: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Meropenem-Vaborbactam in Children With Complicated Urinary Tract Infection, Including Acute Pyelonephritis

Recruiting
2
66
Europe, US, RoW
Meropenem-Vaborbactam, Vabomere, Antibiotics
Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC), Biomedical Advanced Research and Development Authority
Acute Pyelonephritis, Complicated Urinary Tract Infection
01/27
07/27
2016-000656-99: Dose-finding, Pharmacokinetics, and Safety of VABOMERE in Pediatric Subjects With Bacterial Infections

Not yet recruiting
1
67
US
Meropenem + Vaborbactam, Powder for concentrate for solution for infusion, VABOMERE®; VABOREM®
Rempex Pharmaceuticals-Melinta Therapeutics, Rempex Pharmaceuticals-Melinta Therapeutics, Menarini I.F.R.
Suspected or confirmed negative bacterial infection, Serious bacterial infection, Diseases [C] - Bacterial Infections and Mycoses [C01]
 
 
TANGOKIDS, NCT02687906 / 2016-000656-99: Dose-finding, Pharmacokinetics, and Safety of VABOMERE in Pediatric Subjects With Bacterial Infections

Recruiting
1
67
US
Vabomere, Combination meropenem and vaborbactam, carbapenem and beta-lactamase inhibitor
Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC), Department of Health and Human Services
Bacterial Infections
06/25
06/25
Baxdela (delafloxacin) / Menarini, Melinta Therap
NCT06612255: A Study Comparing the Bioavailability of a Taste-masked Delafloxacin Powder for Oral Suspension With the Delafloxacin Tablet in Healthy Adults

Terminated
1
16
Europe
Delafloxacin, Baxdela, Quofeni, Delabaxi, RX-3341, ABT-492, ABT-319492, WQ-3034, Delafloxacin Powder
Melinta Therapeutics, Inc., Biomedical Advanced Research and Development Authority
Healthy
09/24
09/24
Minocin for injection (minocycline intravenous) / Melinta Therap
2020-005162-33: Treatment of inflammation with Minocycline in depressed patients Trattamento dell’infiammazione con Minociclina in pazienti depressi

Ongoing
2
60
Europe
(R)-[N-metil-11C]PK11195, Minocic, [(R)-N-metil-11CPK11195], [n/a], Solution for injection, Tablet, Minocin
IRCCS CENTRO SAN GIOVANNI DI DIO - FATEBENEFRATELLI AFFERENTE ALLA PROVINCIA LOMBARDO VENETA ORDINE OSPEDALIERO DI SAN G, Ministero della Salute
depressed patients with high levels of inflammation (crp>2 mg/l) and non responder to at least two different antidepressants depressione maggiore con alti livelli infiammatori (crp>2 mg/l) e non responder a due farmaci antidepressivi differenti, depressed patients with high levels of inflammation and non responder to at least two different antidepressants pazienti depressi che presentano alti livelli di infiammazione e non rispondono a due trattamenti antidepressivi diversi, Diseases [C] - Nervous System Diseases [C10]
 
 
ACTRN12611001053910: The West Australian Intravenous Minocycline and tissue plasminogen activator (TPA) Stroke Study (WAIMATSS)

Recruiting
1/2
50
 
Sir Charles Gairdner Hospital, West Australian Institute for Medical Research
Ischaemic stroke
 
 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Nuvocid (oritavancin) / Melinta Therap, Menarini
COPAT, NCT05977868: Comparing Oral Versus Parenteral Antimicrobial Therapy

Terminated
4
90
US
Amoxicillin, amoxicillin-clavulanate, cefadroxil, cefpodoxime, cefalexin, ciprofloxacin, delafloxacin, doxycycline, levofloxacin, linezolid, metronidazole, moxifloxacin, rifampin, trimethoprim-sulfamethoxazole, Ampicillin, ampicillin-sulbactam, cefazolin, cefepime, ceftaroline, ceftazidime, ceftazidime-avibactam, dalbavancin, daptomycin, ertapenem, meropenem, oritavancin, oxacillin, penicillin, piperacillin-tazobactam, tigecycline, vancomycin
West Virginia University
Endovascular Infection, Bone and Joint Infection, Skin and Soft Tissue Infection, Pulmonary Infection, Gastrointestinal Infection, Genitourinary Infection
02/25
02/25
AIM-STOP, NCT05521880: Anchoring Sequential Intermittent Long Acting Antimicrobials With Medication for Opioid Use Disorder (MOUD) for Invasive Infections Related to Opioid Use

Terminated
4
2
US
Oritavancin
University of Maryland, Baltimore
Substance Use Disorders, Infection, Soft Tissue, Bacteremia, Osteomyelitis Acute, Septic Arthritis
05/25
05/25
2022-001297-63: A Multicenter, Open-Label, Evaluator-Blinded, Randomized Study to Evaluate the Safety and Tolerability of Single-Dose IV Oritavancin Versus Standard of Care for the Treatment of Pediatric Subjects with Acute Bacterial Skin And Skin Structure Infections

Ongoing
2
200
Europe
ORBACTIV®, KIMYRSA, Clindamycin, Teicoplanin, Vancomycin, Cafazolin, Ceftaroline, Sulfamethoxazole/trimetoprime, Lyophilisate for solution for infusion, Solution for infusion, Powder and solvent for solution for injection/infusion, Powder for concentrate for solution for infusion, Powder for solution for injection/infusion, Oral suspension, ORBACTIV®, KIMYRSA
Melinta Therapeutics, LLC, Melinta Therapeutics, LLC
Acute Bacterial Skin and Skin Structure Infections, Bacterial infection of the skin and associated tissues., Diseases [C] - Skin and Connective Tissue Diseases [C17]
 
 
ML-ORI-201, NCT05599295 / 2022-001297-63: Study to Evaluate the Safety and Tolerability of Single-Dose Intravenous (IV) Oritavancin

Recruiting
2
200
Europe, US
Oritavancin
Melinta Therapeutics, LLC, Melinta Therapeutics, LLC
Acute Bacterial Skin and Skin Structure Infection
06/25
01/26
NCT02134301 / 2013-005415-26: Open-Label, Dose-Finding, Pharmacokinetics, Safety and Tolerability Study of Oritavancin in Pediatric Patients With Suspected or Confirmed Bacterial Infections

Recruiting
1
52
US
Oritavancin
Melinta Therapeutics, LLC
Gram Positive Bacterial Infections
06/25
06/25
ORI-4-CIEDi, NCT07013552: Oritavancin for CIED Infections With MDR Gram-positive Cocci

Not yet recruiting
N/A
100
Europe
Administration of a single or repeated dose of a long half-life antibiotic - oritavancin, Administration of a repeated dose of a short half-life antibiotic - vancomycin
Medical University of Silesia, Medical Research Agency, Poland
Cardiac Implantable Electronic Device Infections, Infective Endocarditis, Multidrug-resistant Bacteria Screening, Gram Positive Bacterial Infection, Antibiotic Resistant Strain, Antibiotic Therapy, Healthcare Associated Infections
07/26
10/26
Rezzayo (rezafungin for injection) / Cidara Therap, Mundipharma, Melinta Therap
NCT06985758: Pharmacokinetic Study of Rezafungin in Patients With Suspected Intra-Abdominal Candidiasis

Not yet recruiting
4
20
Europe
Rezafungin 400mg followed by weekly doses of intravenous Rezafungin 200mg, Rezafungin
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
Candidal Peritonitis
11/25
01/26
ReSPECT, NCT04368559 / 2017-004981-85: Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation

Recruiting
3
600
Europe, Canada, US, RoW
Rezafungin for Injection, Intravenous antifungal therapy, Posaconazole, Noxafil, Fluconazole, Generic Fluconazole, Trimethoprim-sulfamethoxazole (TMP/SMX), Bactrim, Septra, Intravenous Placebo, Placebo Infusion, Oral Placebo, encapsulated cellulose
Mundipharma Research Limited
Candidemia, Mycoses, Fungal Infection, Fungemia, Invasive Candidiasis, Pneumocystis, Mold Infection, Invasive Fungal Disease, Prophylaxis of Invasive Fungal Infections, Aspergillus
12/25
12/25
NCT06774144: Rezafungin Prophylaxis in Liver Transplant

Enrolling by invitation
3
385
US
Rezafungin, Standard of care antifungal prophylaxis, Fluconazole, voriconazole, or no prophylaxis
Fernanda P Silveira, MD, MS, Melinta Therapeutics
Liver Transplant Infection, Fungal Infection
12/28
12/28
NCT05835479: Rezafungin for Treatment of Pneumocystis Pneumonia in HIV Adults

Recruiting
2
50
RoW
Co-Trimoxazole, Rezafungin Acetate / Co Trimoxazole
Mundipharma Research Limited
Pneumocystis Pneumonia
05/25
08/25
NCT06794554: Rezafungin for Treatment of Chronic Pulmonary Aspergillosis (CPA) in Adults with Limited Treatment Options

Not yet recruiting
2
60
NA
Rezafungin Acetate
Mundipharma Research Limited
Chronic Pulmonary Aspergillosis
02/26
07/26
NCT06329518: Rezafungin Pharmacokinetics in Patients on ECMO

Withdrawn
1
8
NA
Rezafungin, rezafungin acetate
Hartford Hospital, Melinta Therapeutics, LLC
Sepsis
12/24
12/24
NCT05534529: Rezafungin Paediatric PK Study in Paediatric Subjects From Birth to <18 Years of Age

Terminated
1
32
Europe
Rezafungin Acetate, Rezafungin
Mundipharma Research Limited
Invasive Fungal Infections
05/24
10/24
Vabomere (meropenem/vaborbactam) / Melinta Therap, Menarini
2021-003847-10: A study comparing a 7-day versus a 14-day course of antibiotics against an infection affecting the blood caused by a bacteria called Pseudomonas aeruginosa. Estudio en el que se compara un tratamiento con antibióticos de 7 días frente a uno de 14 días de duración contra una infección que afecta a la sangre producida por una bacteria llamada Pseudomonas aeruginosa.

Ongoing
4
304
Europe
Tablet, Solution for infusion, Powder for infusion, Powder for solution for infusion, Ciprofloxacin, Levofloxacin, Piperacillin/Tazobactam, Ceftazidime, Cefepime, Ceftazidime/Avibactam, Ceftolozane/Tazobactam, Imipenem, Meropenem, Meropenem-Vaborbactam, Colistin, Amikacin, Tobramycin, Aztreonam
Fundación Pública Andaluza para la Gestión de la Investigación en Salud de Sevilla (FISEVI), ICI21/00075 (ISCIII)
Adult patients with bloodstream infections produced by Pseudomonas aeruginosa. Pacientes adultos con bacteriemia producida por Pseudomonas aeruginosa., Adult patients with infections that produce the passing of Pseudomonas aeruginosa bacteria to the blood. Pacientes adultos con infecciones que producen el paso de bacterias de Pseudomonas aeruginosa a la sangre., Diseases [C] - Bacterial Infections and Mycoses [C01]
 
 
TREAT-GNB, NCT07004049: Optimising TREATment for Severe Gram-Negative Bacterial Infections

Recruiting
4
600
Europe, RoW
Colistin/Polymyxin B + Sulbactam, Colistin/Polymyxin B + Tigecycline/Eravacycline, Colistin/Polymyxin B + Meropenem, Ceftazidime-avibactam + Sulbactam, Ceftazidime-avibactam + Fosfomycin, Ceftazidime-avibactam, Ceftazidime-avibactam + Aztreonam, Ceftazidime-avibactam + Colistin/Polymyxin B, High-dose meropenem, Meropenem + Fosfomycin, Meropenem-vaborbactam, Cefiderocol, Ceftolozane-tazobactam, Ceftolozane-tazobactam + Meropenem
National University of Singapore, The University of Queensland, European Clinical Research Alliance for Infectious Diseases (ECRAID)
Bloodstream Infection, Ventilator Associated Bacterial Pneumonia, Hospital Acquired Bacterial Pneumonia, Carbapenem Resistant Bacterial Infection, Multidrug Resistance
12/28
12/28
2014-000545-78: A randomized, double-blind double-dummy Phase 3 study performed at multiple study sites to evaluate the safety, efficacy and tolerability of the combinational product Carbavance (Meropenem/RPX7009) in comparison to Piperacillin/Tazobactam which is already approved in many countries to treat patients with complicated urinary tract infections, including acute pyelonephritis, in adults.

Ongoing
3
80
Europe
Carbavance, Meropenem/RPX7009, Tazobac EF, Piperacillin/Tazobactam-Teva 4g/0,5g, Tazobac EF, Piperacillin/Tazobactam-Teva 4g/0,5g
Rempex Pharmaceuticals, Inc., Rempex Pharmaceuticals Inc., Biomedical Advanced Research and Development Authority (BARDA)
complicated urinary tract infection (cUTI) or acute pyelonephritis (AP) with or without concurrent bacteremia
 
 
VABOR-KIDS-01, NCT06828848: A Study to Assess How Vaborem® is Taking up in the Body and Tolerated in Paediatric Patients With Complicated Urinary Tract Infection

Recruiting
2
32
Europe, RoW
Meropenem plus vaborbactam
Menarini Group
Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis
07/26
07/26
NCT06672978: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Meropenem-Vaborbactam in Children With Complicated Urinary Tract Infection, Including Acute Pyelonephritis

Recruiting
2
66
Europe, US, RoW
Meropenem-Vaborbactam, Vabomere, Antibiotics
Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC), Biomedical Advanced Research and Development Authority
Acute Pyelonephritis, Complicated Urinary Tract Infection
01/27
07/27
2016-000656-99: Dose-finding, Pharmacokinetics, and Safety of VABOMERE in Pediatric Subjects With Bacterial Infections

Not yet recruiting
1
67
US
Meropenem + Vaborbactam, Powder for concentrate for solution for infusion, VABOMERE®; VABOREM®
Rempex Pharmaceuticals-Melinta Therapeutics, Rempex Pharmaceuticals-Melinta Therapeutics, Menarini I.F.R.
Suspected or confirmed negative bacterial infection, Serious bacterial infection, Diseases [C] - Bacterial Infections and Mycoses [C01]
 
 
TANGOKIDS, NCT02687906 / 2016-000656-99: Dose-finding, Pharmacokinetics, and Safety of VABOMERE in Pediatric Subjects With Bacterial Infections

Recruiting
1
67
US
Vabomere, Combination meropenem and vaborbactam, carbapenem and beta-lactamase inhibitor
Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC), Department of Health and Human Services
Bacterial Infections
06/25
06/25
Baxdela (delafloxacin) / Menarini, Melinta Therap
NCT06612255: A Study Comparing the Bioavailability of a Taste-masked Delafloxacin Powder for Oral Suspension With the Delafloxacin Tablet in Healthy Adults

Terminated
1
16
Europe
Delafloxacin, Baxdela, Quofeni, Delabaxi, RX-3341, ABT-492, ABT-319492, WQ-3034, Delafloxacin Powder
Melinta Therapeutics, Inc., Biomedical Advanced Research and Development Authority
Healthy
09/24
09/24
Minocin for injection (minocycline intravenous) / Melinta Therap
2020-005162-33: Treatment of inflammation with Minocycline in depressed patients Trattamento dell’infiammazione con Minociclina in pazienti depressi

Ongoing
2
60
Europe
(R)-[N-metil-11C]PK11195, Minocic, [(R)-N-metil-11CPK11195], [n/a], Solution for injection, Tablet, Minocin
IRCCS CENTRO SAN GIOVANNI DI DIO - FATEBENEFRATELLI AFFERENTE ALLA PROVINCIA LOMBARDO VENETA ORDINE OSPEDALIERO DI SAN G, Ministero della Salute
depressed patients with high levels of inflammation (crp>2 mg/l) and non responder to at least two different antidepressants depressione maggiore con alti livelli infiammatori (crp>2 mg/l) e non responder a due farmaci antidepressivi differenti, depressed patients with high levels of inflammation and non responder to at least two different antidepressants pazienti depressi che presentano alti livelli di infiammazione e non rispondono a due trattamenti antidepressivi diversi, Diseases [C] - Nervous System Diseases [C10]
 
 
ACTRN12611001053910: The West Australian Intravenous Minocycline and tissue plasminogen activator (TPA) Stroke Study (WAIMATSS)

Recruiting
1/2
50
 
Sir Charles Gairdner Hospital, West Australian Institute for Medical Research
Ischaemic stroke
 
 

Download Options